REG - Futura Medical PLC - Result of AGM

Futura MedicalAnnouncement

20/06/2024 16:15

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240620:nRST2789Ta&default-theme=true

RNS Number : 2789T  Futura Medical PLC  20 June 2024

20 June 2024

Futura Medical plc

("Futura", "the Group" or the "Company")

Result of AGM

 

Futura Medical plc (AIM: FUM), the consumer healthcare company behind
Eroxon®, that specialises in the development and global commercialisation of
innovative and clinically proven sexual health products, today announces that
at its Annual General Meeting, held today at 10:00am BST, the shareholders
duly passed all resolutions.

 

The total number of votes received on each resolution were as follows:

 

 

                                                                                                    Voting For                                                    Voting Against
                     Number of votes(i)                                                             %                              Number of votes                %                                Total Votes                      % ISC        Votes withheld(ii)
 Resolution 1        To receive and adopt the annual report and accounts for the financial year     145,896,305                    99.50                          738,451                          0.50                             146,634,756  48.57       121,536
                     ended 31 December 2023
 Resolution 2        That Roy Davis be and is hereby appointed as a Director of the Company.        146,637,030                    99.98                          30,544                           0.02                             146,667,574  48.58       91,718
 Resolution 3        To re-elect Angela Hildreth as a Director of the Company, who retires by       146,583,928                    99.94                          80,896                           0.06                             146,664,824  48.58       91,468
                     rotation in accordance with

                     the Company's articles of association.
 Resolution 4        To re-appoint Grant Thornton UK LLP as auditor of the Company to hold office   146,559,436                    99.95                          74,813                           0.05                             146,634,249  48.57       122,043
                     until the conclusion of

                     the next annual general meeting of the Company.
 Resolution 5        To authorise the Directors to determine the remuneration of Grant Thornton UK  146,544,066                    99.95                          68,860                           0.05                             146,612,926  48.56       143,366
                     LLP as auditor of the

                     Company
 Resolution 6        That the Directors are generally and unconditionally authorised for the        146,000,585                    99.50                          735,009                          0.50                             146,735,594  48.60       20,698
                     purposes of section 551

                     Companies Act 2006 (the "CA 2006") to exercise all the powers of the Company
                     to allot shares in the

                     Company and to grant rights to subscribe for or to convert any security into
                     shares in the Company.
 Resolution 7(iii)   Disapplication of pre-emption rights                                           145,446,404                    99.13                          1,279,733                        0.87                             146,726,137  48.60       30,155
 Resolution 8 (iii)  Disapplication of pre-emption rights in respect of an additional 20% of the    146,060,258                    99.54                          669,879                          0.46                             146,730,137  48.60       26,155
                     company issued share capital

 

ⁱ Where shareholders appointed the Chairman as their proxy with discretion
as to voting, their votes were cast in favour of the resolution

ⁱⁱ A vote withheld is not a vote in law and is not counted towards the
votes cast "For" or "Against" a resolution

ⁱⁱⁱ Special Resolution (75% majority required)

The total voting rights of the Company as at 10:00 am on 18 June 2024 (the
time by which shareholders wanting to vote at the AGM were required to be
entered on the register) was 301,863,641 ordinary shares of 0.2p each. The
Company does not hold any shares in treasury.

 

 

 

Contacts:

 Futura Medical plc              James Barder               investor.relations@futuramedical.com

                          (mailto:Investor.relations@futuramedical.com)
                                 Chief Executive Officer

                          +44 (0)1483 685 670
                                 Angela Hildreth

                          www.futuramedical.com (http://www.futuramedical.com/)
                                 Finance Director and COO

 Liberum                         Richard Lindley            +44 (0)20 3100 2000

 Nominated Adviser               Nikhil Varghese

 and Broker

 Stifel Nicolaus Europe Limited  Alan Selby                 +44 (0)207 710 7600

 Joint Broker                    Ben Maddison

 Alma Strategic Communications   Rebecca Sanders-Hewett     +44 (0)20 3405 0205

                                 Sam Modlin                 futura@almastrategic.com

                                 Will Ellis Hancock

 

Notes to Editors:

Futura Medical plc (AIM: FUM) is the developer of innovative sexual health
products, including lead product Eroxon. Our core strength lies in our
research, development and commercialisation of topically delivered gel
formulations in sexual health products.

Eroxon, Futura's clinically proven lead product, has been developed for the
treatment of Erectile Dysfunction ("ED"). The highly differentiated product,
which is the only topical gel treatment for ED available over the counter and
helps men get an erection in ten minutes, addresses significant unmet needs
in the ED market.

ED impacts 1 in 5 men globally across all adult age brackets, with
approximately half of all men over 40 experiencing ED and 25% of all new
diagnoses being in men under 40.

Futura has distribution partners in place in a number of major consumer
markets including Haleon in the US, the largest market for ED in the world,
and Cooper Consumer Health in Europe. Eroxon has been nominated for a number
of healthcare industry awards and has won two to-date.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  RAGURAVRSAUNUAR